[Federal Register Volume 62, Number 101 (Tuesday, May 27, 1997)]
[Notices]
[Pages 28721-28722]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-13830]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Vaccine for Malaria

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice in accordance with 15 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), 
Department of Health and Human Services, is contemplating the grant of 
a limited field of use exclusive world-wide license to practice the 
invention embodied in U.S. Patent Application Serial Nos. 08/119,677 
(field 09/10/93), 08/487,826 (field 06/07/95), and 08/568,459 (filed 
12/07/95), entitled ``Binding Domains from Plasmodium Vivax and 
Plasmodium Falciparum Erythrocyte Binding Proteins,'' and related 
foreign patent applications, to EntreMed, Inc. of Rockville, MD. The 
patent rights in these inventions have been assigned to the United 
States of America.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
It is anticipated that this license may be limited to vaccine for 
Malaria.
    This prospective exclusive license may be granted unless within 60 
days from the date of this published notice, NIH receives written 
evidence and argument that establishes that the grant of the license 
would not be consistent with the requirements of 35 U.S.C. 209 and 37 
CFR 404.7.

SUPPLEMENTARY INFORMATION: The patent applications identify function 
domains of Plasmodium proteins which can be used for the prevention or 
treatment of malaria. The parasite invades erythrocytes by attaching to 
surface receptors. The erthyrocyte binding domains of the sialic acid 
binding protectin (SABP) of P. falciparum and the Duffy antigen binding 
protein (DABP) can be used in vaccines to induce immune responses which 
block erythrocyte binding and invasion by P. falciparum and P. vivax 
meroszoites. USSN 089/487,826 further includes genes and nucleotide 
sequences and predicted polypeptide sequences of the P. falciparum DBL 
(Duffy-binding like) gene family which codes for antigenically variant 
binding domains.

ADDRESSES: Requests for a copy of the patent applications, inquiries, 
comments and other materials relating to the contemplated license 
should be directed to: Gloria H. Richmond, Patent Advisor, Office of 
Technology Transfer, National Institutes of Health, 6011 Executive 
Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: 301/496-
7057; Facsimile: 301/402-0200; E-mail: Gloria [email protected]. A 
signed Confidential Disclosure Agreement will be required to receive a 
copy of the patent applications.
    Applications for a non-exclusive or exclusive license filed in 
response to

[[Page 28722]]

this notice will be treated as objections to the grant of the 
contemplated license. Only written comments and/or applications for a 
license which are received by NIH on or before July 28, 1997 will be 
considered.
    Comments and objections submitted in response to this notice will 
not be made available for public inspection, and, to the extent 
permitted by law, will not be released under the Freedom of Information 
Act, 5 U.S.C. 552.

    Dated: May 15, 1997.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 97-13830 Filed 5-23-97; 8:45 am]
BILLING CODE 4140-01-M